1. Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy

3. Introduction

4. Program Overview

5. RAAS Inhibitors Are Recommended to Improve Outcomes in Patients With CKD and Comorbidities

6. Potential Risks in Patients With CKD on RAAS Inhibitor Therapy

7. RAAS Inhibition Benefit vs Risk: A Dichotomy

8. RCTs Support the Use of MRAs Across the CV Continuum

9. Establishing the Role of MRAs in Patients With CKD

10. Elevated Serum Potassium Is Associated With Increased Mortality in At-Risk Populations

11. Multiple Studies Have Demonstrated the Benefits of RAAS Inhibitor Therapy

12. Multiple Studies Have Demonstrated the Benefits of RAAS Inhibitor Therapy (cont)

13. Multiple Studies Have Demonstrated the Benefits of RAAS Inhibitor Therapy (cont)

14. Using Maximum vs Submaximum Doses of RAAS Inhibitors Is Associated With Reductions in Mortality

15. Evidence-Based Doses of RAAS Inhibitors From Key HFrEF Trials

16. Traditional Interventions for the Management of Chronic Hyperkalemia

17. Newer Agents for the Treatment of Hyperkalemia: Patiromer

18. OPAL-HK: Patiromer in Patients with CKD and Hyperkalemia Receiving RAAS Inhibitors

19. Patiromer Is Effective for the Initial Treatment of Hyperkalemia: OPAL-HK (Part A)

20. Patiromer Helps to Maintain RAAS Inhibitor Dose: OPAL-HK (Part B)

21. OPAL-HK: Most Common AEs

22. AMETHYST-DN: Patiromer Reduces Serum Potassium in Patients With Diabetic Kidney Disease

23. AMETHYST-DN: Most Common AEs Occurring in ≥ 5% of Patients

24. PEARL-HF: Patiromer Reduces Serum Potassium in Patients With HF

25. PEARL-HF: Uptitration of Spironolactone and Incidence of Hyperkalemia

26. Area of Clinical Interest: Use of Patiromer in Patients With ESRD on HD

27. AMBER: Rationale and Study Design

28. Newer Agents for the Treatment of Hyperkalemia: SZC

29. SZC Treatment Among Outpatients With Hyperkalemia: HARMONIZE

30. HARMONIZE: Change in Serum Potassium Over Time (Randomized Phase)

31. HARMONIZE: AEs Reported in ≥ 5% of Patients

32. SPS for the Management of Hyperkalemia

33. Optimizing the Use of RAAS Inhibitors in Cardiorenal Patients

34. When Should a Potassium Binder Be Started?

35. RAAS Inhibitor Use vs Hyperkalemia: Historical Perspective

36. Cardiorenal Patients Are Dependent on RAAS Inhibitors

37. Hyperkalemia Is Common: Data From PARADIGM-HF

38. Management of Hyperkalemia in Patients Taking RAAS Inhibitors

39. Summary and Conclusions

40. Summary and Conclusions (cont)

41. Abbreviations

42. Abbreviations (cont)

43. Abbreviations (cont)